Beate Schultheis

6.2k total citations · 1 hit paper
85 papers, 4.3k citations indexed

About

Beate Schultheis is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Beate Schultheis has authored 85 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 31 papers in Oncology and 26 papers in Genetics. Recurrent topics in Beate Schultheis's work include Chronic Myeloid Leukemia Treatments (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Eosinophilic Disorders and Syndromes (14 papers). Beate Schultheis is often cited by papers focused on Chronic Myeloid Leukemia Treatments (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Eosinophilic Disorders and Syndromes (14 papers). Beate Schultheis collaborates with scholars based in Germany, United Kingdom and United States. Beate Schultheis's co-authors include Junia V. Melo, John M. Goldman, Dirk Strumberg, Michael W. Deininger, J. Chabrol, Josy Reiffers, François Xavier Mahon, Andreas Hochhaus, Nicholas C.P. Cross and Karin Battmer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Beate Schultheis

84 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

2000 616 citations Beate Schultheis, John M. Goldman et al. Blood profile →

Peers

Beate Schultheis

HEMAT

GENET

ONCOL

RHEUM

John Nicoll United States

Prithviraj Bose United States

Clayton A. Smith United States

Katherine R. Calvo United States

Niels Pallisgaard Denmark

Ulrike Bacher Germany

Gerald M. Segal United States

Dina Ben‐Yehuda Israel

Stephen T. Oh United States

Dale L. Bixby United States

John Nicoll United States

Beate Schultheis

1.9k ×1.0

HEMAT

935 ×0.6

1.4k ×1.1

GENET

506 ×0.5

ONCOL

919 ×1.0

RHEUM

Citations per year, relative to Beate Schultheis Beate Schultheis (= 1×) peers John Nicoll

Countries citing papers authored by Beate Schultheis

Since Specialization

Citations

This map shows the geographic impact of Beate Schultheis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beate Schultheis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beate Schultheis more than expected).

Fields of papers citing papers by Beate Schultheis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beate Schultheis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beate Schultheis. The network helps show where Beate Schultheis may publish in the future.

Co-authorship network of co-authors of Beate Schultheis

This figure shows the co-authorship network connecting the top 25 collaborators of Beate Schultheis. A scholar is included among the top collaborators of Beate Schultheis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beate Schultheis. Beate Schultheis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schultheis, Beate, Dirk Reuter, M. Ebert, et al.. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology. 28(10). 2429–2435. 97 indexed citations

Doğan, Aşkın, et al.. (2017). Melanoma of the Vagina: Case Report and Systematic Review of the Literature. Anticancer Research. 37(12). 6911–6920. 20 indexed citations

Bahleda, Rastislav, Juneko E. Grilley‐Olson, Ramaswamy Govindan, et al.. (2017). Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer. 116(12). 1505–1512. 22 indexed citations

Strumberg, Dirk, Beate Schultheis, Ansgar Santel, et al.. (2013). Antimetastatic Activity of Atu027, a Liposomal Sirna Formulation, Targeting Protein Kinase N3: Final Results of a Phase I Study. Annals of Oncology. 24. i7–i7. 3 indexed citations

Reinwald, Mark, Michael Hummel, Birgit Spieß, et al.. (2012). Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. Journal of Antimicrobial Chemotherapy. 67(9). 2260–2267. 80 indexed citations

Schultheis, Beate, Dirk Strumberg, Lothar Bergmann, et al.. (2011). Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Investigational New Drugs. 30(3). 1184–1192. 12 indexed citations

Schultheis, Beate, et al.. (2011). Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 69(2). 333–339. 10 indexed citations

Strumberg, Dirk, Beate Schultheis, Christiane Vank, et al.. (2011). Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 50(1). 76–78. 112 indexed citations

Schultheis, Beate, et al.. (2011). Angioimmunoblastic T-cell lymphoma, combined with antiphospholipid syndrome and autoimmune thrombocytopenia (Case Report). International Journal of Clinical Pharmacology and Therapeutics. 50(1). 74–75. 2 indexed citations

10.

Strumberg, Dirk, Beate Schultheis, M. E. Scheulen, et al.. (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 473–475. 12 indexed citations

11.

Schultheis, Beate, et al.. (2010). Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach – a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 451–452. 1 indexed citations

12.

Metzgeroth, Georgia, Melanie Kripp, Nadine Müller, et al.. (2009). The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. Clinical Chemistry and Laboratory Medicine (CCLM). 47(10). 1291–5. 7 indexed citations

13.

Richly, Heike, Beate Schultheis, Irenä us A. Adamietz, et al.. (2008). Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial. European Journal of Cancer. 45(4). 579–587. 68 indexed citations

14.

Metzgeroth, Georgia, Beate Schultheis, Christian Kühn, et al.. (2007). The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia. Clinical Chemistry and Laboratory Medicine (CCLM). 45(10). 1313–8. 9 indexed citations

15.

Metzgeroth, Georgia, Walter Back, Beate Schultheis, et al.. (2006). Intestinal‐type adenocarcinoma situated in the nasopharynx. Cytopathology. 18(1). 59–63. 3 indexed citations

16.

Radujkovic, Aleksandar, Julian Topaly, Marlon R. Veldwijk, et al.. (2005). Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19(7). 1198–1206. 78 indexed citations

17.

Schultheis, Beate, et al.. (2002). Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood. 99(5). 1766–1775. 70 indexed citations

18.

Krämer, A., Beate Schultheis, Jean‐François Bergmann, et al.. (2002). Alterations of the cyclin D1/pRb/p16INK4A pathway in multiple myeloma. Leukemia. 16(9). 1844–1851. 50 indexed citations

19.

Schultheis, Beate, et al.. (1999). Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia?. Leukemia. 13(S1). S55–S64. 3 indexed citations

20.

Schultheis, Beate, A. Krämer, Andreas Willer, et al.. (1999). Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 13(12). 2099–2103. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact